Genetic and Transcriptional Contributions to Relapse in Acute Myeloid Leukemia

10/25/2021

sponsored by 10x Genomics

For patients with acute myeloid leukemia (AML) treated with chemotherapy, the contribution of genetic heterogeneity to drug resistance and disease progression has been well-established. More recently, studies have begun to investigate the impact of transcriptional heterogeneity to tumor adaptability. However, bulk RNA-sequencing has lacked the resolution to allow the identification of canonical, relapse-associated transcriptional changes. To better understand relapse-associated clonal and transcriptional adaptation, Dr. Allegra Petti and colleagues turned to enhanced whole genome sequencing (eWGS) and ultra-deep single cell RNA-sequencing (scRNA-seq) to examine the correlation between genetic and transcriptional evolution.

Join this webinar, to hear Dr. Petti discuss the findings of this study and learn about:

How integration of eWGS and scRNA-seq enabled quantitative measurement of the co-evolution of genetic and transcriptional heterogeneity and resolved subclone-specific states
Findings indicating that clonal evolution does not represent all relevant biological changes
The identification of leukemic cells seeding resistance

Available On-Demand

Visit our Webinar Hub

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.